MSB Mesoblast Ltd.

Mesoblast Corporate Update and Financial Results Webcast

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021).

Conference Call Details 

The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via /mesoblast-limited/20201119/NaN5fb59c68f297810019932232

The archived webcast will be available on the Investor page of the Company’s website:

About Mesoblast

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. 

Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. 

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see , LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Release authorized by the Chief Executive.

For further information, please contact:

Media

Julie Meldrum

T:

E:		Kristen Bothwell

T:

E:
  
Investors

Schond Greenway

T:

E: 		Paul Hughes   

T:

E:  



EN
19/11/2020

Underlying

MSBMesoblast Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesoblast Ltd.

 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Successful Commercial Launch of Ryoncil®

Successful Commercial Launch of Ryoncil® Activity Report for Quarter Ended June 30, 2025 (Appendix 4C) NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first quarter post product launch. Ryoncil® is the first and only FDA mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving F...

July 18, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Ap...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. In follow-up to the successful Type B ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway ...

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF...

June 12, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil...

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another m...

May 15, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. “We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy in the US for any indication,” said Dr. Silviu Itesc...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch